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Considerable evidence indicates that glucocorticoid hormones en-
hance the consolidation of long-term memories for emotionally
arousing experiences but not that for less arousing or neutral
information. However, previous studies have not determined the
basis of such arousal-induced selectivity. Here we report the
finding that endogenous noradrenergic activation of the basolat-
eral complex of the amygdala (BLA) induced by emotional arousal
is essential in enabling glucocorticoid memory enhancement. Cor-
ticosterone administered immediately after object recognition
training enhanced 24-h memory of naı¨ve male rats but not that of
rats previously habituated to the training context in order to
reduce novelty-induced emotional arousal. The -adrenoceptor
antagonist propranolol administered either systemically or into the
BLA blocked the corticosterone-induced memory enhancement.
Further, in habituated rats, corticosterone activated BLA neurons,
as assessed by phosphorylated cAMP response element binding
(pCREB) immunoreactivity levels, and enhanced memory only
when norepinephrine release was stimulated by administration of
the 2-adrenoceptor antagonist yohimbine. These findings
strongly suggest that synergistic actions of glucocorticoids and
emotional arousal-induced noradrenergic activation of the BLA
constitute a neural mechanism by which glucocorticoids may se-
lectively enhance memory consolidation for emotionally arousing
experiences.
corticosterone  emotional arousal  norepinephrine  object recognition 
memory consolidation
Extensive evidence indicates that emotionally arousing expe-riences are typically well remembered (1, 2). Investigations of
the underlying neurobiological mechanisms suggest that glu-
cocorticoids, released from the adrenal cortex by emotional
arousal, play a key role in the strengthening of new memory
traces (3–5). Recent findings of both animal and human studies
suggest that glucocorticoids may selectively modulate the con-
solidation of memories of emotionally arousing stimuli (6–9) or
those of experiences occurring during states of emotional arousal
(10). Such findings imply that glucocorticoids interact with some
other component of emotional arousal in influencing memory
consolidation. We reported evidence that selective blockade of
noradrenergic activity in the basolateral complex of the amyg-
dala (BLA) of rats with infusions of a -adrenoceptor antagonist
prevented the memory-enhancing effects of glucocorticoids
administered either systemically or into selected brain regions
(11–13). Such findings, considered along with the evidence that
emotional arousal activates the BLA (14–19) and induces the
release of norepinephrine within the BLA (20, 21), suggest that
emotional arousal-induced noradrenergic activation within the
BLA may be essential in enabling glucocorticoid effects on
memory consolidation. However, because prior experiments
investigating glucocorticoid-noradrenergic interactions on mem-
ory consolidation have used training conditions that induce the
release of high levels of norepinephrine in the BLA (20, 21), such
studies did not determine whether glucocorticoid enhancement
of memory requires emotional arousal-induced noradrenergic
activation of the BLA or, alternatively, whether glucocorticoids
enhance memory consolidation by activating the release of
norepinephrine in the BLA.
The aim of the present experiments was to investigate whether
noradrenergic activation of the BLA triggered specifically by the
emotionally arousing properties of the training experience is crit-
ically involved in enabling glucocorticoid effects on memory con-
solidation. In these experiments, rats were trained on an object
recognition task. Although no rewarding or aversive stimulation is
used during object recognition training (22), we previously had
found that such training stimulates novelty-induced emotional
arousal in naı¨ve rats and that extensive prior habituation to the
experimental context attenuates such arousal during training (9).
Thus, rats were exposed to the objects while in a state of arousal or
in a less aroused state. We previously found that corticosterone
selectively enhances the consolidation of object recognition mem-
ory when administered to nonhabituated (i.e., emotionally aroused)
rats immediately after the training trial (9). Thus, if noradrenergic
activation of the BLA induced by the novelty stress is necessary for
enabling the glucocorticoid effect on memory consolidation, then
(i) blockade of noradrenergic activation should prevent corticoste-
rone-induced memory enhancement in nonhabituated rats, (ii)
pharmacological stimulation of norepinephrine release should en-
able corticosterone-induced memory enhancement for objects ex-
perienced in a familiar low-arousing context, and (iii) -adreno-
ceptor activation within the BLA should be critically involved in
enabling these glucocorticoid effects on memory consolidation.
Our findings provide strong support for each of these implications.
Additionally, we found that corticosterone activated BLA neurons
only when noradrenergic activity was stimulated concurrently.
Results
Blockade of Noradrenergic Activity Prevents Corticosterone Effects on
Memory Enhancement in Nonhabituated Rats. Context-naı¨ve male
Sprague–Dawley rats were trained on an object recognition task
and received a vehicle solution or corticosterone (0.3, 1.0, or 3.0
mgkg, s.c.) either alone or coadministered with the -adreno-
ceptor antagonist propranolol (3.0 mgkg, s.c.) immediately
after the training. During the 3-min training trial, before drug
treatment, the groups spent comparable times exploring each of
two identical objects (one-sample t tests: P  0.33) and also did
not differ in total times exploring both objects (one-way
ANOVA: F7,77  1.62; P  0.14; see Table 2, which is published
as supporting information on the PNAS web site). We previously
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found that rats readily remember such training when tested at a
1-h retention interval (9). Two-way ANOVA for 24-h retention
performance revealed significant corticosterone (F3,77  2.70;
P  0.05) and propranolol effects (F1,77  10.52; P  0.05), as
well as a significant interaction between both factors (F3,77 
4.02; P  0.05). On the 24-h retention test, the vehicle-treated
group did not show significant preference for the novel object
versus the object explored during training (one-sample t test: P
0.76), but rats given the 1.0 and 3.0 mgkg doses of corticoste-
rone posttraining exhibited a highly significant preference for
the novel object (one-sample t tests: P  0.0004; Fig. 1A).
Blockade of noradrenergic activity with posttraining injections
of propranolol administered alone did not affect object recog-
nition retention performance (P  0.43 vs. vehicle) but pre-
vented the retention enhancement induced by corticosterone
(P  0.24 vs. propranolol). The groups did not differ in total
times exploring both objects during the retention test trial
(one-way ANOVA: F7,77  1.26; P  0.28; see Table 2). These
findings indicate that noradrenergic activity is essential to enable
glucocorticoid effects on memory consolidation with training
conditions that produce mild novelty-induced emotional arousal
and thus not only, as reported previously, with highly arousing
training (11–13, 23).
Pharmacologically Induced Noradrenergic Activation Mimics the Ef-
fect of Emotional Arousal in Enabling Corticosterone Effects on
Memory Enhancement in Habituated Rats. As indicated, we previ-
ously reported that corticosterone does not enhance the con-
solidation of object recognition memory in rats given extensive
prior habituation to the training context to reduce novelty-
induced emotional arousal (9). If the failure of corticosterone to
enhance memory consolidation in context-habituated rats is due
selectively to insufficient arousal-induced noradrenergic activa-
tion, then posttraining pharmacological augmentation of nor-
adrenergic activity should provide the activation normally pro-
duced by novelty stress and enable glucocorticoid enhancement
of memory consolidation. To examine this implication, a low
dose of the 2-adrenoceptor antagonist yohimbine (0.3 mgkg,
s.c.), which increases norepinephrine levels in the brain (24), was
administered to habituated rats either alone or together with
corticosterone, immediately after object recognition training
(Fig. 1B). This dose of yohimbine was selected because it does
not enhance the consolidation of object recognition memory in
habituated rats (Table 1). During the 3-min training trial, before
drug treatment, the groups spent comparable times exploring
each of two identical objects (one-sample t tests: P  0.39) and
also did not differ in total times exploring both objects (one-way
ANOVA: F7,80 0.45; P 0.79; see Table 2). Two-way ANOVA
for 24-h retention performance revealed significant corticoste-
rone (F3,89  5.84; P  0.005) and yohimbine effects (F1,89 
24.88; P  0.0001), as well as a significant interaction between
both factors (F3,89 3.97; P 0.01). Posttraining administration
of corticosterone alone failed to induce a preference for the
novel object on the retention test (one-sample t tests: P  0.62).
Moreover, although yohimbine administered alone also did not
affect retention performance (P  0.18 vs. vehicle), corticoste-
rone administered concurrently with yohimbine induced dose-
dependent retention enhancement (1.0 mgkg: P  0.0001 vs.
yohimbine) comparable with that of rats not given prior habit-
uation. Posttraining injections of the two drugs separated by a
4-h delay did not induce a preference for the novel object on the
retention trial (one-sample t tests: P 0.83; Fig. 1B Inset). These
findings thus indicate that glucocorticoid effects on memory
consolidation normally require emotional arousal-induced nor-
adrenergic activation. However, pharmacologically stimulated
noradrenergic activity fully mimics the effects of emotional
arousal in enabling glucocorticoid enhancement of memory
consolidation under low-arousing training conditions.
Corticosterone Effects on Memory Enhancement Require Noradren-
ergic Activity Within the Basolateral Amygdala. Findings of animal
and human studies provide extensive evidence that emotionally
arousing experiences activate the amygdala and that such activity
(especially of the BLA) modulates memory consolidation (5,
14–19). Furthermore, emotionally arousing training experiences
induce the release of norepinephrine within the amygdala (20,
Fig. 1. Glucocorticoid effects on memory consolidation for object recogni-
tion training require noradrenergic activation. Data represent discrimination
index (%) on a 24-h retention trial, expressed as mean  SEM. (A) Effects of
immediate posttraining administration of the -adrenoceptor antagonist
propranolol (3.0 mgkg, s.c.) on corticosterone-induced enhancement of
object recognition memory in naı¨ve rats. **, P  0.0001 vs. vehicle (n  8–12
per group). (B) Effect of coadministration of the 2-adrenoceptor antagonist
yohimbine (0.3 mgkg, s.c.) with corticosterone on object recognition memory
in habituated rats. **, P  0.0001 vs. vehicle (n  9–17 per group). (B Inset)
Effect of posttraining injections of yohimbine (0.3 mgkg, s.c.) and cortico-
sterone (1.0 mgkg, s.c.) separated by a 4-h delay. Y3C, yohimbine adminis-
tered immediately after training and corticosterone 4 h later; C3Y, cortico-
sterone administered immediately after training and yohimbine 4 h later.
Table 1. Effect of yohimbine on object recognition memory
Yohimbine No prior habituation Prior habituation
Saline 1.8  6.5 2.0  3.3
0.1 mgkg 15.8  4.2* 1.5  3.6
0.3 mgkg 35.8  4.8* 2.2  7.3
1.0 mgkg 16.5  5.3* 2.2  4.0
3.0 mgkg 0.01  5.4 27.8  4.0*
Data represent discrimination index (%) on the 24-h retention test trial,
expressed as mean  SEM. One-way ANOVA revealed significant treatment
effects in naı¨ve rats (F4,52  8.88, P  0.0001) as well as in habituated rats
(F4,55  9.77, P  0.0001). Yohimbine was administered subcutaneously im-
mediately after the training trial. *, P  0.05 as compared with the corre-
sponding saline group (n  10–17 per group).
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21). To examine whether glucocorticoid effects on object rec-
ognition memory depend on noradrenergic activity within the
BLA, propranolol (0.5 g per hemisphere; see Fig. 2A for
infusion site) was infused bilaterally into the BLA of nonhab-
ituated rats immediately after object recognition training, and
corticosterone was then immediately administered systemically.
Because the hippocampus is also highly sensitive to the effects
of glucocorticoids (25, 26) but does not seem to play a critical
role in object recognition memory (27, 28), other groups of rats
received posttraining infusions of propranolol (1.25 g per
hemisphere) into the dorsal hippocampus (see Fig. 2B for
infusion site). The groups did not differ in total exploration times
of the two objects during training (one-way ANOVA: BLA,
F7,71  1.08, P  0.39; hippocampus, F7,86  0.41, P  0.89) or
testing (BLA: F7,71  0.69, P  0.68; hippocampus: F7,86  0.20,
P  0.98; see Table 3, which is published as supporting infor-
mation on the PNAS web site). Two-way ANOVA for 24-h
retention performance of rats administered vehicle or cortico-
sterone systemically and either saline or propranolol into the
BLA revealed significant corticosterone (F3,71  2.95; P  0.05)
and propranolol effects (F1,71  17.66; P  0.0001), as well as a
significant interaction between both factors (F3,71  3.49; P 
0.05). Post hoc analysis revealed that posttraining intra-BLA
infusions of propranolol blocked 24-h retention enhancement
induced by immediate posttraining administration of corticoste-
rone (P 0.31 vs. propranolol; Fig. 2C). In contrast, posttraining
infusions of propranolol into the dorsal hippocampus did not
block the corticosterone-induced enhancement (Fig. 2D). These
findings thus indicate that glucocorticoid-induced enhancement
of memory consolidation depends selectively on noradrenergic
activation within the BLA.
Corticosterone Effects on Basolateral Amygdala Neuronal Activity
Require Arousal-Induced Noradrenergic Activation. To examine
whether arousal induced by object recognition training induces
noradrenergic activation in the BLA and whether such activation
is necessary for mediating glucocorticoid effects on BLA activ-
ity, we first determined the immunoreactivity for phosphory-
lated (i.e., activated) tyrosine hydroxylase (pTH) (29), the
rate-limiting enzyme in the biosynthesis of norepinephrine (30),
in brains of habituated and nonhabituated rats. One-way
ANOVA for pTH immunoreactivity in the BLA revealed a
significant group effect (F7,34  9.81; P  0.0001). Object
recognition training increased the density of pTH-positive fibers
in the BLA of nonhabituated rats by 100% 3 h after training
(P  0.0001 vs. home cage controls; Fig. 3 A and B). Further-
more, double staining with dopamine--hydroxylase, the en-
zyme that converts dopamine into norepinephrine, revealed a
nearly 100% overlap with pTH immunoreactivity (data not
shown), indicating that arousal induced by object recognition
training induces a marked increase in TH activity and local
synthesis of norepinephrine in the BLA. Prior habituation of rats
to the experimental context significantly reduced the density of
pTH-positive fibers assessed 3 h after object recognition training
(P  0.001 vs. nonhabituated counterparts) and induced only a
trend toward an increase from home cage controls that had
received similar habituation training (28% increase; P 0.06).
Training-induced increases in pTH immunoreactivity in the
BLA resulted from phosphorylation of existing TH, because
habituated and nonhabituated rats did not differ in total (i.e.,
phosphorylated and nonphosphorylated) TH immunoreactivity
in BLA fibers and nerve terminals (P  0.54; data not shown).
Importantly, corticosterone (1.0 mgkg) administered posttrain-
ing did not alter pTH immunoreactivity in the BLA of either
habituated or nonhabituated rats (P  0.62; Fig. 3 A and B),
indicating that, under these conditions, corticosterone did not
enhance memory consolidation by increasing the local synthesis
of norepinephrine in the BLA. Furthermore, arousal-induced
increases in noradrenergic activity, as assessed by pTH, were
found in the BLA but not the hippocampus. Prior habituation,
object recognition training, or corticosterone administration all
failed to alter pTH immunoreactivity levels in the dentate gyrus
(one-way ANOVA: F7,34  0.24, P  0.97; Fig. 3C) or CA1
region of the hippocampus (data not shown).
Our finding that corticosterone-induced memory enhance-
ment requires noradrenergic activation but does not increase
pTH immunoreactivity in BLA fibers and nerve terminals
suggests that corticosterone interacts with training-induced nor-
adrenergic activation at a postsynaptic level, possibly via an
activation of membrane-bound glucocorticoid receptors (31), in
increasing BLA neuronal activity (13). To assess postsynaptic
BLA neuronal activity, we determined immunoreactivity for the
phosphorylated form of the transcription factor cAMP response
element-binding (pCREB) protein. Noradrenergic stimulation
induces pCREB activation (32, 33), and several findings have
implicated CREB phosphorylation in the amygdala in the mod-
ulation of memory consolidation (33–35). One-way ANOVA for
pCREB immunoreactivity in the BLA revealed a significant
group effect (F7,34  5.58; P  0.0005). In nonhabituated rats,
posttraining corticosterone (1.0 mgkg) administration signifi-
cantly increased the number of pCREB-positive neurons in the
BLA 3 h after training (P  0.05 vs. vehicle; Fig. 3 A and B).
However, in habituated rats, posttraining corticosterone or
yohimbine administered alone did not significantly increase the
number of pCREB-positive BLA neurons. Importantly, how-
ever, corticosterone administered together with yohimbine sig-
nificantly increased pCREB immunoreactivity in the BLA (P 
0.01 vs. yohimbine). Thus, these findings indicate that cortico-
sterone activates the BLA, as assessed by pCREB, only under
training conditions that induce sufficient noradrenergic activa-
tion within the BLA. In contrast, no training-related or treat-
ment-related increases in pCREB immunoreactivity were found
in either the dentate gyrus (one-way ANOVA: F7,34  0.19, P 
Fig. 2. Activation of -adrenoceptors in the BLA, but not the hippocampus,
is required for enabling corticosterone effects on object recognition memory.
Data represent discrimination index (%) on a 24-h retention trial, expressed as
mean SEM. (A and B) Diagram and photomicrograph illustrating placement
of infusion needle tip in the BLA and hippocampus. The arrow points to the
needle tip. (C) Effect of posttraining administration of the -adrenoceptor
antagonist propranolol (0.5 g per hemisphere) into the BLA on corticoste-
rone-induced enhancement of object recognition memory in nonhabituated
rats. **, P 0.0001 vs. vehicle (n 8–11 per group). (D) Effect of posttraining
administration of the -adrenoceptor antagonist propranolol (1.25 g per
hemisphere) into the hippocampus on corticosterone-induced enhancement
of object recognition memory in nonhabituated rats. *, P  0.05; **, P 
0.0001 vs. vehicle (n  10–14 per group).








0.98; Fig. 3C) or CA1 region of the hippocampus (F7,34  0.04,
P  1.00; data not shown).
Discussion
The objective of this study was to investigate whether glucocorticoid
effects on memory consolidation require emotional arousal-
induced increases in noradrenergic activity. To examine this issue,
the present experiments used the strategy of training rats on an
object recognition task in an experimental context that induces
either an aroused or less aroused emotional state. In an earlier
study, we found that extensive prior habituation to the training
context decreases emotional arousal induced by the training, as
assessed by both behavioral and neuroendocrine measures (9).
Corticosterone administered immediately after the training expe-
rience selectively enhanced memory of rats that were naı¨ve to the
experimental context. Results of human studies examining the role
of emotional arousal by varying the emotionally arousing content of
the learning material have also suggested that glucocorticoids
(administered before learning) selectively enhance memory for
emotionally arousing information (6), although some studies re-
ported different effects (8, 36). Consistent with our findings,
Abercrombie et al. (10) reported that levels of endogenous cortisol
correlated with enhanced memory consolidation only in individuals
who were emotionally aroused. It is, of course, possible that the
glucocorticoid-induced memory enhancement seen in these human
studies was due, at least in part, to increased attentional bias to
arousing stimuli experienced during the encoding. Importantly, in
the present experiments, the drugs were administered immediately
after training to influence memory consolidation and to exclude
any influence of the drugs on information encoding. Moreover,
total exploration of the objects exhibited during training was not
greater in nonhabituated (i.e., emotionally aroused) rats (see Table
2) and retention performance of habituated and nonhabituated
vehicle-treated controls did not differ from each other.
Blockade of noradrenergic activity with a -adrenoceptor
antagonist administered immediately after object recognition
training to nonhabituated (i.e., emotionally aroused) rats pre-
vented the corticosterone-induced memory enhancement. Con-
versely, stimulating noradrenergic activity with the 2-
adrenoceptor antagonist yohimbine enabled glucocorticoid
memory enhancement in rats that had a reduced emotional
arousal response because of prior habituation. Thus, although
emotional arousal is known to induce a myriad of peripheral and
central physiological responses (37), our findings indicate that
selective manipulation of noradrenergic activity after training is
sufficient to either block or mimic the influence of emotional
arousal in enabling the facilitating effects of posttraining glu-
cocorticoid administration on memory consolidation. Moreover,
the finding that posttraining administrations of yohimbine and
corticosterone separated by a 4-h delay did not induce memory
enhancement supports the hypothesis that both arousal systems
need to be activated together. Thus, these findings strongly
suggest that glucocorticoids enhance memory for emotionally
arousing experiences because of critical interactions with en-
dogenous noradrenergic activation induced by the training ex-
perience and make it very unlikely that glucocorticoids enhance
memory by stimulating the release of norepinephrine or that
basal levels of norepinephrine are sufficiently high to enable
glucocorticoid effects on memory consolidation.
Our findings further indicate that glucocorticoid-induced
enhancement of memory consolidation for object recognition
training requires, in particular, noradrenergic activation within
the BLA. We found that object recognition training in a novel,
but not familiar, environment increased pTH immunoreactivity
(i.e., noradrenergic activation) in the BLA, and that blockade of
this noradrenergic activity with a -adrenoceptor antagonist
infused into the BLA prevented glucocorticoid enhancement of
object recognition memory. Corticosterone administration did
not alter pTH immunoreactivity in the BLA of either habituated
Fig. 3. Prior habituation attenuates the effects of object recognition training and corticosterone (Cort) injection on noradrenergic activity within the BLA. (A)
Photomicrographs of the amygdala depicting pTHSer19 and pCREB immunostaining as assessed 3 h after training. Overviews of the amygdala of home cage
controls (no prior habituation) (Top), and pTH (Middle) and pCREB (Bottom) in the BLA. (Top) The delineated areas indicate the regions analyzed for optical
density (pTH) or cell counts (pCREB). (B and C) Summary of the immunocytochemistry data for the BLA and dentate gyrus (mean SEM). *, P 0.05; **, P 0.01
vs. home cage (for pTH) or vehicleyohimbine (for pCREB);, P 0.001 prior habituation vs. corresponding no prior habituation group (n 5–6 per group).
CEA, central amygdala.
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or nonhabituated rats. However, corticosterone required nor-
adrenergic activation induced either by the training experience
or the yohimbine administration to increase BLA neuronal
activity, as assessed by increases in pCREB immunoreactivity, a
transcription factor necessary for memory processes (34, 38, 39).
These findings thus suggest that corticosterone interacts with
training-induced noradrenergic activation at a postsynaptic level,
possibly via an activation of membrane-bound glucocorticoid
receptors (31), in increasing BLA neuronal activity and enhanc-
ing memory consolidation (13). Such findings fit with previous
evidence on an inhibitory avoidance task indicating that glu-
cocorticoids or the specific glucocorticoid receptor agonist RU
28362 enhance memory consolidation by potentiating -adre-
noceptor-cAMP-dependent protein kinase signaling in the BLA
(13). Moreover, previous studies reported similar synergistic
effects of glucocorticoids and the noradrenergic system on
pCREB activation in regulating other cellular functions (40, 41).
Such findings indicating that noradrenergic activation within the
BLA plays a central role in regulating glucocorticoid effects on
memory consolidation are also consistent with extensive prior
evidence indicating that noradrenergic activity of the BLA, but
not the adjacent central nucleus, is critically involved in memory
consolidation and mediates the memory-modulatory effects of
drugs affecting a variety of neurotransmitter systems (5, 42–44).
Furthermore, the findings are in accord with evidence from
functional imaging studies in human subjects indicating that
amygdala activity during encoding of emotional activity corre-
lates with subsequent retention performance (14) and that both
the amygdala activity and subsequent retention are attenuated
by propranolol administered before encoding (16, 18). In view of
the extensive evidence that BLA activation influences memory
consolidation via projections to other brain regions involved in
processing recent information (5), it is likely that the enhanced
memory seen in the present study was mediated by influencing
activity in the perirhinal and insular cortices (45), because these
brain regions are known to be critically involved in object
recognition memory (27, 46–48).
In contrast to the BLA, glucocorticoid-induced memory en-
hancement for object recognition memory did not require
noradrenergic activation within the hippocampus. The hip-
pocampus has been implicated in the detection of novel contexts
but not novel objects (46, 47), and noradrenergic activity within
the hippocampus may be involved in memory of novel contexts
(49). Thus, although our findings indicating that object recog-
nition training in a novel environment did not significantly alter
pTH and pCREB immunoreactivity levels in the hippocampus
may be unexpected, the present findings are consistent with
results of lesion studies suggesting that the hippocampus is not,
or only minimally, involved in memory of objects (27, 28).
However, glucocorticoids may interact with noradrenergic
mechanisms in the hippocampus in influencing the consolidation
of contextualspatial information. Previous findings have shown
that the infusion of either a glucocorticoid receptor agonist or
-adrenoceptor agonist into the hippocampus enhances memory
of such training (50, 51). Furthermore, it has been reported that
hippocampal excitability (52), as well as the stress-induced
modulation of long-term potentiation in the hippocampus, de-
pends on both glucocorticoid and -adrenergic influences (53–
55). However, glucocorticoid effects in the hippocampus on
memory consolidation of contextualspatial training also re-
quire concurrent noradrenergic activity within the BLA (12).
The present findings provide increased understanding of the
role of glucocorticoids and arousal-induced noradrenergic acti-
vation within the BLA in modulating the consolidation of
memory for emotionally arousing experiences. As extensive
evidence indicates that the memory-modulatory effects of many
drugs depend on an intact BLA (5), it seems likely that the
present findings may be relevant for other drug systems as well.
These results may thus have important consequences for drug
development, because potential cognitive-enhancing drugs may
modulate memory consolidation only under conditions that
induce sufficient noradrenergic activation of the BLA.
Materials and Methods
Subjects. Male Sprague–Dawley rats (350–450 g) from Charles
River Laboratories were maintained on a 12-h12-h lightdark
cycle (lights on: 0700–1900 h) with ad libitum access to food and
water. All procedures complied with National Institutes of Health
guidelines and were approved by the University of California,
Irvine, Institutional Animal Care and Use Committee.
Object Recognition Test. The experimental apparatus was a gray
open-field box (40 cm 40 cm 40 cm) with a sawdust-covered
floor, placed in a dimly illuminated room (9). The objects to be
discriminated were white glass light bulbs (6 cm diameter by 11
cm length) and transparent glass vials (5.5 cm diameter by 5 cm
height). One group of rats was not habituated to the experi-
mental context, whereas the other group was habituated exten-
sively to decrease their novelty stress to the apparatus during the
training trial. During habituation, the rats were allowed to freely
explore the apparatus in the absence of objects twice per day for
3 min each for 7 days. On the training trial, the rat was placed
in the experimental apparatus and allowed to explore two
identical objects (A1 and A2) for 3 min. To avoid the presence
of olfactory trails, sawdust was stirred and the objects were
thoroughly cleaned with 70% ethanol between rats. Retention
was tested after 24 h. One copy of the familiar object (A3) and
a new object (B) were placed in the same location as stimuli
during the training trial. All combinations and locations of
objects were counterbalanced to reduce potential biases because
of preference for particular locations or objects. The rat was
placed in the experimental apparatus for 3 min and the time
spent exploring each object and the total time spent exploring
both objects were recorded. Exploration of an object was defined
as pointing the nose to the object at a distance of 1 cm andor
touching it with the nose. Turning around, climbing or sitting on
an object was not considered as exploration. A discrimination
index was calculated as the difference in time exploring the novel
and familiar object, expressed as the ratio of the total time spent
exploring both objects. Rats showing a total exploration time
10 s on either training or testing were excluded.
Cannula Implantation. Rats were implanted bilaterally with guide
cannulae aimed at either the BLA [anteroposterior (AP), 2.8
mm from bregma; mediolateral (ML), 5.0 mm from midline;
dorsoventral (DV), 6.5 mm from skull surface] or dorsal
hippocampus [AP, 3.3 mm; ML, 1.7 mm; DV, 2.7 mm]
based on Paxinos and Watson (56). After behavioral testing, rats
were perfused with 4% formaldehyde, and their brains were
sectioned at 50-m thickness, stained with cresyl violet, and
examined by light microscopy. Rats (n  26) with injection
needle placements outside the BLA or the hippocampus or with
extensive tissue damage at the injection needle site were ex-
cluded from analyses.
Drug Treatment. Systemically administered drugs were given s.c. (2.0
mlkg) immediately after the training trial. Corticosterone (0.3, 1.0,
or 3.0 mgkg; Sigma) was dissolved in 5% ethanol in saline, and
propranolol (3.0 mgkg; Sigma) and yohimbine (0.1, 0.3, 1.0, or 3.0
mgkg; Sigma) were dissolved in saline. For BLA infusions, the
injection needles protruded 2.0 mm beyond the cannula tip, and a
0.2-l injection volume of saline or propranolol (0.5 g) per
hemisphere was infused over 25 s. For hippocampus infusions, the
injection needles protruded 1.5 mm beyond the cannula tip and a
0.5-l injection volume of saline or propranolol (1.25 g) per
hemisphere was infused over 35 s. Drug doses were selected on the








basis of extensive prior evidence (11–13). All drug solutions were
freshly prepared before each experiment.
Immunocytochemistry. Rats were perfused with 4% paraformal-
dehyde. Selected sections (25 m) were treated with 0.3% H2O2,
blocked with 3% normal serum, and the cell membrane was
permeabilized with 0.1% Triton-X100. The primary antibodies
TH (rabbit anti-tyrosine hydroxylase, AB151, 1:3000; Chemi-
con), pTH (rabbit anti-tyrosine hydroxylase phosphoSer19,
AB5425, 1:3000; Chemicon; and rabbit anti-tyrosine hydroxylase
phosphoSer40, 1:3000, Cell Signaling Technology, Beverly,
MA), or pCREB (rabbit anti-Ser-133-phosphorylated CREB,
1:300; Cell Signaling Technology) were applied for 24 h at 4°C.
Sections were incubated with a biotinylated secondary antibody
(goat anti-rabbit or goat anti-mouse, 1:400, Jackson Immuno-
Research) for 2 h at room temperature, followed by incubation
with avidin-biotin complex (1:400, ABC elite kit; Vector Lab-
oratories) for 2 h. Staining was visualized with 20 mg per 100 ml
3,3-diaminobenzidine (DAB) and 0.03% H2O2.
For pTHdopamine--hydroxylase double labeling, sections
were incubated for 24 h with the primary antibodies pTH and
dopamine--hydroxylase (mouse anti-dopamine--hydroxylase,
MAB308, 1:1000; Chemicon), followed by Cy5-conjugated don-
key anti-rabbit and rhodamine red-conjugated donkey anti-
mouse F(ab) fragments (1:200; Jackson ImmunoResearch).
Double labeling was studied by using a Zeiss LSM510 confocal
laser and scanning microscope.
Quantitative Analyses of Immunoreactivity. pTH and TH immuno-
staining (pTHSer19 immunoreactivity was analyzed because of
the better quality of the immunostaining as compared with
pTHSer40, although both antibodies showed similar quantitative
results) was quantified by using a Quantimet 600 image analysis
system, whereas pCREB was quantified by counting the immu-
nopositive nuclei by using an ocular counting frame. Optical
density (OD) for pTH and TH and cell counts for pCREB were
determined in the BLA and the dentate gyrus and CA1 region
of dorsal hippocampus (at bregma level2.2 to3.6, according
to standard atlas plates of ref. 56). OD of the immunostained
fibers is expressed in arbitrary units corresponding to gray levels.
Cell counts are expressed as number of pCREB nuclei per mm2.
Quantitative analysis of OD and cell counts were performed
blind to the experimental treatment.
Statistics. Data are expressed as mean SEM. Statistical analysis
used one- or two-way ANOVAs, followed by post-hoc compar-
ison tests. One-sample t tests assessed whether the discrimination
index differed from zero. P  0.05 was accepted as statistical
significance.
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